Zolmitriptan Spray
Product Images NDC 71335-2947

Product Visual Gallery

This gallery contains 9 technical images submitted to the FDA as part of the official labeling for Zolmitriptan (NDC 71335-2947). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure 1 (Image 01)

A line chart depicting the estimated probability of response (%) over hours from initial dose for zolmitriptan nasal spray at 2.5 mg and 5.0 mg doses, compared with placebo. The chart shows response rates increasing over four hours, with the 5.0 mg dose highest, followed by 2.5 mg, and placebo lowest.*

FDA Label Image

Figure 2 (Image 02)

Line graph comparing the estimated probability (%) of taking an escape medication over 24 hours after initial dose for zolmitriptan nasal sprays at 2.5 mg and 5.0 mg doses versus placebo. The x-axis represents hours from initial dose, and the y-axis shows the probability percentage. The 5.0 mg nasal spray shows the highest probability increase, followed by placebo and then the 2.5 mg nasal spray.*

FDA Label Image

Figure 3 (Image 03)

A line graph showing estimated probability (%) of rescue medication use over 24 hours post-dose for zolmitriptan 5 mg nasal spray compared to placebo. Time post dose in hours is plotted on the x-axis and probability on the y-axis. The graph includes two lines with symbols representing zolmitriptan and placebo groups.*

FDA Label Image

Figure-a (Image 04)

Illustration showing hands opening a foil packet of zolmitriptan nasal spray USP 5 mg, demonstrating how to access the nasal spray by peeling back the packet.*

FDA Label Image

Figure B (Image 05)

An instructional illustration labeled 'Figure B' shows a woman using her index finger to close one nostril, demonstrating how to properly administer zolmitriptan nasal spray by closing one nostril during use.*

FDA Label Image

Figure-c (Image 06)

An instructional diagram showing a hand holding a zolmitriptan nasal spray device labeled with parts identified as the nozzle and plunger. The image focuses on demonstrating the device components for administration of zolmitriptan nasal spray.*

FDA Label Image

Figure D (Image 07)

An instructional illustration labeled Figure D showing a person positioning a nasal spray for administration. The individual holds the spray device near one nostril, with the other hand pointing to the opposite nostril, demonstrating proper nasal spray technique.*

FDA Label Image

Chemical-structure (Image 10)

Chemical structure of zolmitriptan, showing the molecular arrangement including an indole ring, a morpholine ring, and a dimethylaminoethyl side chain typical of this compound.*

FDA Label Image

Label (Lbl713352947)

Zolmitriptan Nasal Spray USP 5 mg label showing a package of 6 single-use spray devices. The label includes the NDC 71335-2947-1 and notes relabeling by Bryant Ranch Prepack, Inc., with manufacturing by Padagis. It states the spray contains 5 mg of zolmitriptan in a 100-µL unit dose aqueous buffered solution, for intranasal use only.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.